Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
New Mexico Cancer Research Alliance
With
University of New Mexico Cancer Center
Lovelace Respiratory Research Institute
The goal of this trial is to demonstrate the potential clinical benefit of targeted irinotecan chemotherapy in NSCLC patients whose tumors display a specific phenotype that is associated with increased sensitivity to this drug, ISG15H.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
INCLUSION:
18 years of age or older Have received prior chemotherapy for histologically proven advanced non-small cell lung cancer, up to 3 prior treatments Tumors display high ISG15 (ISG15H) at screening Life expectancy of at least 12 weeks ECOG/Zubrod performance status of 0-2 Provide informed consent permission to participate
Adequate bone marrow function as follows:
1\. Absolute neutrophil count of greater than or equal to 1,500 or cells/mm3, and 2) Platelet count greater than or equal to 100,000/mm3 and 3) Absence of a regular red blood cell transfusion requirement
Adequate hepatic function with:
1. Total bilirubin less than or equal to 4.0 mg/dl, and
2. SGOT or SGPT less than or equal to four times ULN
Adequate renal function as defined by:
1\) Serum creatinine less than or equal to 1.5 x ULN
You may not be if
Symptomatic brain metastases
Pregnant women or nursing mothers
Patients of child bearing potential must use adequate contraception.
May not be receiving other concurrent chemotherapy or radiation therapy
Severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections
Previous hypersensitivity reaction to camptothecins
Clareo Health | Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
